Loading...
•
Sep 30, 2021
Design Therapeutics Q3 2021 Earnings Report
Reported pipeline progress and third quarter 2021 financial results.
Key Takeaways
Design Therapeutics reported a net loss of $11.3 million for the third quarter ended September 30, 2021. The company's lead GeneTACTM program for Friedreich Ataxia is on track for clinical initiation in the first half of 2022.
Design Therapeutics remains on track to initiate a Phase 1 clinical trial in patients with FA in the first half of 2022, with initial topline clinical data expected in 2022.
Design reported new preclinical data from its novel DM1 GeneTACTM program at the 2021 Virtual Myotonic Dystrophy Foundation Annual Conference in September 2021.
João Siffert, M.D., president and chief executive officer and Sean Jeffries, Ph.D., chief operating officer, will participate in a fireside chat during the 33rd Annual Virtual Piper Healthcare Conference, being held November 30 – December 2, 2021.
As of September 30, 2021, the company had cash, cash equivalents and investment securities of $393.7 million.
Forward Guidance
Design Therapeutics expects 2022 will be a milestone-rich and transformational year for the company.
Positive Outlook
- Initiation of the clinical program in Friedreich ataxia.
- Progress with our myotonic dystrophy type-1 GeneTACTM program.
- Expansion of our pipeline with several earlier stage programs.
- Treating additional diseases caused by nucleotide repeat expansions.
- Advancements across our pipeline and GeneTACTM platform.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...